ARCHIVES

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 7 | July 27, 2012

Download PDF Visit The Full Archive

Related Articles

DCT Advisors Approve $22 Mil. Set Aside For Interactive R01s Systemic Therapies

July 10, 1992

Drug Development: FDA Grants Breakthrough Therapy Designation To CTL019 in ALL

June 11, 2014

Adding Ultrasound Revealed More Breast Cancers In Study

May 30, 2008

Fox Chase Symposium Tro Focus On Year 2000 Goals

August 21, 1987

Cooperative Groups Get Reprieve From Cut As Budget Is Flatlined At Fiscal 2006 Level.

June 8, 2007

Analysis Reveals CAIX Subgroup Responsive to Rencarex Therapy

June 28, 2013